Standard BioTools (STU:FLB) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FLB Standard BioTools Inc STU:FLB
39 GF Score
Price €0.75
GF Value €0.46
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Standard BioTools Valuation Rank Related Terms

STU:FLB
39GF Score
Standard BioTools Inc STU:FLB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46. GuruFocus considers Standard BioTools to be Significantly Overvalued.

Key valuation signals for STU:FLB:

  • Valuation Rank:
  • GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score

Get the complete analysis for STU:FLB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price
€0.46
GF Value